Please select the option that best describes you:
Topics:
Sarcoma • Medical Oncology
At what lower end of recurrence risk do you offer adjuvant imatinib for patients with resected GIST?
What is your preferred risk stratification model?
There does not appear to be a consensus among experts as to what cutoff in recurrence risk justifies the use, cost, and risks associated with adjuvant imatinib.
Answer from: Medical Oncologist at Academic Institution
The "lower end of recurrence risk" justifying adjuvant Imatinib is indeed a personalized decision between the provider and the patient based on risk-tolerance on both sides. In the absence of "cost-effectiveness" data, this has to be a mutual decision that works for both sides. In general, <20% r...
Sign in or Register to read more